Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR882 vs Febuxostat in Gout and Hyperuricemia
NCT06603142Phase 3Active, not recruiting
- Sponsor
- Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pozdeutinurad in primary gout and hyperuricemia (3 arms), sponsored by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. Primary endpoint: Percentage of participants with serum uric acid < 360 umol/L at 8 weeks. Started Apr 2024; status: active, not recruiting.
02
Drugs
pozdeutinurad
03
Conditions
primary gouthyperuricemia
Beyond the preview
Go deeper on NCT06603142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603142.